FDA Panel To Weigh DXM Education, Sales Restrictions Against Scheduling
This article was originally published in The Tan Sheet
Executive Summary
The continued availability of OTC dextromethorphan depends on convincing safety experts that less restrictive measures than scheduling DXM as a controlled substance will sufficiently reduce abuse
You may also be interested in...
DXM Panel Proposes Augmenting, Improving Education To Curb Abuse
Members of an FDA panel tipped their hats to the Consumer Healthcare Product Association's efforts to reduce dextromethorphan abuse, but floated enhancements to the program
DXM Panel Proposes Augmenting, Improving Education To Curb Abuse
Members of an FDA panel tipped their hats to the Consumer Healthcare Product Association's efforts to reduce dextromethorphan abuse, but floated enhancements to the program
DXM Panel Proposes Augmenting, Improving Education To Curb Abuse
Members of an FDA panel tipped their hats to the Consumer Healthcare Product Association's efforts to reduce dextromethorphan abuse, but floated enhancements to the program